1. US Patent 6,225,201 B1. Full approval: May 1, 2001

Therapeutic treatment for renal dysfunction by inhibition of protein kinase C.

Inventors (alphabetical order): Richard E Gilbert, Kirk Ways in collaboration with Eli Lilly and Co., Indianapolis, IN.

2. US Patent 7,087,608 B2. Full approval: August 8, 2006

Use of PDGF tyrosine kinase inhibitors for the treatment of diabetic nephropathy.

Inventors (alphabetical order): Robert Atkins, Steven Chadban, Mark Cooper, Richard E Gilbert, Prudence Hill, Darren J Kelly, David Nikolic-Paterson, in collaboration with Novartis Pharma, NJ.

3. World wide filing PCT WO2008003141. PCT July 5, 2007. Priority date July 5, 2006

A new chemical entity for the treatment the prevention of medical illnesses.

Inventors (alphabetical order): Richard E Gilbert, Darren J Kelly, Spencer Williams, Steven Zammit, Henry Krum as co-founders of Fibrotech Pty Ltd, Australia.

A start-up biotechnology company, Fibrotech Therapeutics, was spun out from this invention that went in to early phase clinical trials in 2014 before being acquired by Shire Pharmaceuticals.

4. US PAT050664-US-PCT01. US patent filed July 2010, PCT February 2008

A method for the prevention of, delay progression to overt to, or the treatment of diseases modulated by an increase in tissue bradykinin levels.

Inventors (alphabetical order): Duncan J Campbell, Richard E Gilbert, Darren J Kelly in collaboration with Novartis Pharma, NJ.

5. World wide filing WO/2003/077892 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating angiotensin II mediated diseases

World wide patent filed 2003. Granted in EU: 13.09.2006

Inventors (alphabetical order): David Feldman, Richard E Gilbert, Darren Kelly in collaboration with Novartis Pharma.

6. US Patent US 2015/0246045 A1, September 3, 2015.

Medical Use of a DPP4 inhibitor.

The invention relates to the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3 -methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine for use in a patient being at risk of or having heart failure with preserved ejection fraction (HFpEF).

Date of Patent: December 27, 2016, Inventors: Thomas Klein, Andrew Advani, Kim Connelly, Richard E Gilbert

7. US Provisional Patent 2018/62-678-054, May 30, 2018.

Compounds and use thereof.

This invention relates to the discovery of new chemical entities (NCEs) to combat fibrosis. Inventors: Christopher Stimson, Olivier Barbeau, Heather Tye, Else Gadouleau, Michelle Southey, Claudia Albrecht, Ira Sternberger, Darren Yuen, Richard E Gilbert

8. U.S. Patent Application No.: 62/949,239 - Dec 17, 2019.

Inhibitors of Pyk2 kinase and uses thereof.

This invention relates to the discovery of new chemical entities (NCEs) to combat fibrosis. Inventors: Christopher Stimson, Mark Kerry, Richard E Gilbert

9. U.S. Provisional Patent Serial No. 63/145,757, Filed 02/04/2021.

Kinase inhibitors and uses thereof.

10. U.S. Provisional Patent Serial No. 63/224,729, Filed 07/22/2021.

Methods for treating kidney fibrosis.

11. UK Provisional Patent Serial No. GB2010464.2, Filed 07/08/20.

Novel compounds and pharmaceutical compositions thereof for the treatment of diseases.

12. U.S. Provisional Patent Serial No. 63/126,081, Filed 12/16/2020.

Novel compounds and pharmaceutical compositions thereof for the treatment of diseases.

• National Library of Medicine